November 14, 2013
Abbott’s m2000 menu is rapidly expanding as it recently added another U.S. Food and Drug Administration (FDA)-cleared test for the detection of toxigenic Clostridium difficile (C. difficile), a common and serious bacterial infection. The new test, developed and manufactured by IntelligentMDx (IMDx) of Waltham, Mass., offers an accurate way to aid in the diagnosis of C. difficile-associated disease and to facilitate hospital infection control.
September 16, 2013
Sept. 16, 2013 – With another flu season approaching, Abbott announced it will add a new U.S. Food and Drug Administration-cleared molecular diagnostic test for detection and differentiation of influenza A and influenza B and respiratory syncytial virus (RSV) to their broad infectious disease testing menu. The IMDx Flu A/B and RSV test developed by IntelligentMDx (IMDX) of Cambridge, Massachusetts, is performed on Abbott's m2000 molecular diagnostics system.
June 20, 2013
ABBOTT PARK, Ill., June 20 2013 – Abbott announced today that it has introduced the first FDA-approved Hepatitis C virus (HCV) genotyping test for patients in the United States. The Abbott RealTime HCV Genotype II test determines the specific type or strain (referred to as the genotype) of the HCV virus present in the blood of an HCV-infected individual. Genotyping the HCV virus provides physicians with important information they can use to create a personalized, targeted diagnosis and treatment path to improve clinical outcomes.